Opinion
Video
Managing a Treatment Experienced Patient with nAMD
Author(s):
Ehsan Rahimy, MD, discusses challenges in managing longstanding nAMD patients rotating through anti-VEGF treatments, highlighting the promise of newer therapies like aflibercept 8mg and faricimab.
This is a video synopsis of a discussion involving Ehsan Rahimy, MD, a retina specialist at the Palo Alto Medical Foundation and adjunct faculty at Stanford University School of Medicine. Dr. Rahimy presents a case scenario involving an 80-year-old Caucasian male with chronic wet age-related macular degeneration (AMD).
The patient, who underwent cataract surgery 13 years prior to the AMD diagnosis, has been receiving injections for both eyes for several years, initially with bevacizumab and later switched to aflibercept. Despite treatment, OCT measurements indicate persistent intraretinal fluid and pigment epithelial detachment. Dr. Rahimy emphasizes the significance of addressing persistent fluid in long-term injection patients.
He discusses tightening injection intervals if fluid persists, considering factors like patient compliance. If fluid persists despite interval adjustments, switching to newer agents such as faricimab or a higher dose of aflibercept is considered. Dr. Rahimy underscores the importance of patient preference in selecting treatment options, noting the availability of multiple options reflecting scientific advancements in retina care.
Dr. Rahimy's insights highlight the evolving landscape of AMD treatment and the importance of tailoring management strategies to individual patient needs. The availability of multiple therapeutic options offers flexibility and optimism for improved outcomes in AMD management, marking significant progress in the field over the past decade.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
